AptarGroup (ATR) Wells Fargo 21st Annual Healthcare Conference summary

Leadership priorities and organizational focus

• Emphasis on customer centricity, innovation, and a performance mindset as non-negotiable pillars for the organization.

• Focus on strengthening leading positions while identifying areas for performance improvement and value unlocking.

• Execution identified as the main constraint to value creation, with a push for accountability, agility, and simplification.

• Ongoing listening tour to engage with all organizational levels and customers, aiming to accelerate decision-making and talent management.

Segment performance and regional insights

• Beauty segment underperforms in North America, while Asia and Europe are within long-term targets; LatAm expected to recover soon.

• Closures segment faces production ramp-up and maintenance issues but maintains a strong pipeline and is expected to return to target performance.

• Both Beauty and Closures have strong market fundamentals and long-term customer relationships, but require improved execution.

Pharma segment and innovation strategy

• Emergency medicine destocking expected to have a $65M top-line impact, mostly resolved by Q4, with pharma margins up excluding this effect.

• Prescription and injectable segments show solid growth, with Q2 prescription at 8% and injectable at 9%.

• Unique strategy involves partnering early with biotech firms, supporting drug development from formulation to regulatory approval, and offering flexible value extraction models.

• Focus on patient-centric solutions and user experience, especially as healthcare shifts to virtual and home settings.